ΛCCELERATED ΛCCESS COLLABORATIVE

Programme Update for AAC Board
Wednesday 10ᵗʰ November 2021

Programme Overview
Programmes progressing well and work underway to align our AAC priorities and work programmes with NHSE exec teams

∧CCELERATED ∧CCESS COLLABORATIVE

Key programme updates:

- **Innovation Service**: GDS beta assessment passed on 13th September 2021, allowing the service to move into public beta **(See slide 6).**
- **Demand Signalling:** The Stroke, Learning Disability & Autism, and Mental Health programmes have completed and due for publication **(See slide 7).**
- **Horizon Scanning**: The development of the processes to operationalise the Horizon Scanning vision is underway, in collaboration across AAC partners **(See slide 8)**.
- **Early Stage:** Two workstreams have successfully delivered; NTRK gene fusion testing for advanced is now being offered nationally by all seven NHS Genomic Laboratory Hubs. The HIT refresh horizon scan is complete and alignment with existing infrastructure has been agreed **(See slide 9).**
- **Embedding Research in the NHS:** A series of regional engagement events are underway in collaboration with regional Medical Directors and NIHR CRN to support local health and research leaders, including ICS representatives to prioritise in embedding research **(See slide 10).**
- **MedTech Funding Mandate:** Operational management process for the MTFM 2021/22 policy in place. Press articles on individual technologies supported by the MTFM have been released. **(See slide 11).**
- **AI Award**: Competition 3 closed 7th September 2021, 200 applications received. Round 3 winners to be announced in February 2022 **(See slide 12).**
- **Rapid Uptake Products:** Proposal for onward filtering and selection for Wave 3 complete, this has been approved by the AAC steering group in October 2021. All wave 2 all products with the exception of PCSK9i performing at or above expected trajectory.

Key Policy activities:

- **Inclisiran:** Commercial deal signed, FAD issued, published in drug tariff. Communication to medicines optimisation community and primary care commenced. Discussions with RCGP and BMA ongoing.
- **Adoption and Spread:** Local engagement and evidence gathering concluded and proposals currently under development to enhance the AAC's strategic approach to adoption and spread.

Key Patient and Public Involvement activities:

- **Innovation Service:** On-going feedback being gathered via questionnaires, pop-ups on the site as well as 1:1 interviews with users.
- **Research**: Plan to commission out the management of the service to develop diverse research messages from April 2022. Market engagement event to be planned as first step.
- **RUPS**: Two patient information leaflets coproduced with Asthma UK, Oxford and Wessex AHSNs.
- **MedTech:** Engagement with stakeholders to understand which technologies meet the 2022/23 MTFM criteria.
- **Early Stage**: A series of discover workshops to explore; what patient-facing information is available,
- **AI**: First draft of evaluation learning document on AI study designs reviewed at Aug Evaluation Advisory Group. Aiming to publish end of 21/22.

OLS update:

- The Life Sciences vision was published on 6th July. OLS are working with partners to develop implementation plans for the vision
- The Spending Review has now been launched and is due to conclude on the 27th October 2021
- The Patient Access to Medicines Partnership meeting took place on 10th September and discussed implementation planning under the Life Sciences vision, Strategic Category Management, the NICE methods review and the Innovative Medicines Fund
- The Life Sciences Council is due to meet on 24th November 2021. The Biopharmaceutical CEO Roundtable is scheduled for 2 December

Delivery (RAG):

	Innovation Service	Horizon Scanning	Demand Signalling	Early Stage Support (ATMPs & HITs)	Embedding Research	MedTech Funding Mandate	AI Award	Late Stage support Rapid Uptake Products (RUPs)
Current Position (End Q2)	🟠	🟢	🟢	🟢	🟠	🟠	🟢	🟢
Future Position (End Q3)	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢

🟢 On track to deliver   🟠 Challenges to deliver, confident of mitigation actions   🔴 Significant risk to delivery and limited confidence in mitigations

Key delivery issues/risks:

Risk/Issue	Likelihood	Impact	Total	Mitigation
Risk: Current NHS finance arrangements for H2 means no activity based payment agreements are in place and CCGs are challenging the policy requirements to fund risking compliance. (MTFM)	5	4	9	Working closely with the AHS. Publication of FAQs for H2 Strategic Finance
Risk: Incomplete handover of development from the BJSS team to NHSEI IT contractors will result in knowledge loss or a reduction in pace. (Innovation Service)	4	4	8	A six week handover period has been implemented, joint working, pair programming, knowledge transfer sessions, documentation transfer
Issue: Continued impact of COVID-19 on service delivery and how we build research into recovery. (Research)	4	4	8	Built in to the research resilience and growth programme

Significant Communications and Engagement Activities Across all our Programmes

Communications & Engagement:

- A tour of all 15 Academic Health Science Networks will start in Autumn and run through to January. The AAC team will hear about the challenges of working through the pandemic and reflect on evolving regional and national priorities emerging from the pandemic response.
- On social we marked the NHS 73rd birthday by spotlighting the remarkable work of NHS innovators over the years.
- We have spotlighted across national media the successful roll out of the MedTech Funding Mandate Policy product, placental growth factor (PLGF) testing.
- We published our annual scorecard measuring the impact of our work, former Government Health Minister Lord Bethell responded positively.
- As part of our Rapid Uptake Products (RUPs) programme we published two patient information leaflets and a video, with Asthma UK, Oxford and Wessex AHSNs
- Working with internal and external stakeholders we promoted four new SBRI Healthcare competitions though bulletins, web and social activity.
- We spotlighted several Clinical Entrepreneurs including Brad Gudger, who in his role as one of the Queens Young leaders talked to the Queen about his charity Alike. Dr Rajiv Sethi who won this year's NHS Rising Star award at the NHS England Parliamentary Award and Malone Mukwende interviewed by Time magazine about his work collating pictures and descriptions of different conditions on darker skins
- With support from our partners, we announced the winners of the Pathway Transformation Funding (PTF), and we published a video setting out how the PTF supports NHS organisation to help to introduce optimal lipid management pathways
- With our partners we supported the delivery of two sector facing events focussed on tackling CVD and healthcare inequalities across the UK through a population health management approach and with Novartis we announced the roll out Inclisiran, which resulted in coverage in every UK national media outlet including 4 front page stories.
- In collaboration with the AHSN and Heart UK we launched the first in a series of webinars as part of the new Tackling Cholesterol Together education programme which was announced at Heart UK's annual conference by their Chair
- We supported the launch of the new Life Sciences vision for the UK which will build on the pandemic response to deliver life saving innovations to patients at speed.
- We have received several positive press articles in national newspapers profiling AI Award winners and the work of AAC
- Further Positive coverage relating to the AAC supported Grail cancer blood test
- We published the Excess Treatment Costs guidance, supporting its dissemination via social channels, through bulletins and partner's channels.

Future Priorities:

- **MedTech Funding:** Understand which technologies meet the 2022/23 MTFM criteria, engage with stakeholders on them and carry out analysis to understand current adoption and spread. Support National Tariff Pricing Team on engagement for an Aligned Incentives Payment Scheme. Publish signalling document to the sector in readiness for 2022/23 MTFM. Publish MTFM 22/23 policy guidance document in December 2021.
- **AI:** PPIE in AI research project commenced, report published for Autumn 2021. Round 3 Stage 1 Shortlisting (Oct 21). Round 4 opening for applications (Spring 22)
- **Research**: Regional engagement event delivery and resultant action plans discussed and agreed by early 2022. NHSE/I Research Roadmap development. Managed introduction of the National Contract Values Review. Campaign activity to support greater participation in research.
- **Demand Signalling**: Publication of final reports for Stroke, LDA, and MH and Initiate 'Tranche 2'
- **Early Stage Categories:** Public engagement on Innovative Medicine Fund (IMF) principles. An extensive 'lessons learnt' process to evaluate Wave 1.Develop proposal for phase 2 in collaboration with AAC partners and key stakeholders. Develop a system readiness animation with our partners.
- **Innovation Service**: Run public beta gather feedback and add additional functionality in ongoing and iterative fashion. Prepare communications materials to support public beta phase roll out
- **Vision and Progress**: Implement new process for prioritising inbound requests for targeted scans. Design and develop content for next industry engagement event.
- **Rapid Uptake Products (RUPs) programme:** Communications plan developed to support the announcement of and awareness raising activity in connection to the 22/23 RUPs

Delivery metrics 21-22 financial year Q1 (1 Apr to 30 Jun 2021)

**ΛCCELERATED
ΛCCESS
COLLABORATIVE**

ΛΛC Scorecard Home

Programme: (All)

Period ending: 2021-22 Q1

NHS

1,660
innovators are being worked with

1,673
innovations are receiving support
(1,661 early stage, 12 late stage)

Estimated patient benefits include:

45,119
fewer incorrectly prescribed medicines

1,462
fewer days spent in hospital

178,836
patients accessing our innovations
12% of eligible patients

277
sites accessing our innovations
35% of eligible sites

£33.7M
of in-year costs to the health system

Information on investment secured is not available for the selected period

Information on jobs created is not available for the selected period

Measures of innovation not attributable to the AAC

Supporting commentary

1. Metrics for the newly supported wave 2 Rapid Uptake Products have been developed and are now reported in the AAC Scorecard as standard. Rapid work has also been undertaken to sustain reporting for the subset of ITT/ITP products that have transitioned to the MedTech Funding Mandate.

2. The number of patients accessing our innovations was up 117k by the end of Q1 compared to the same point last year (from 62k to 179k), in spite of the cessation of ITT/ITP and central support for a number of national AHSN programmes. The increase was driven primarily by 23k patients accessing Asthma biologics and FeNO, and quarter-on-quarter growth of 123k patients on High intensity statins. However, this does not necessarily point to an increase over the full course of the year: of particular note is that support for the Atrial Fibrillation programme, impact for which was traditionally reported at the end of each financial year, has now ceased. AF historically contributed approximately 150k patients to the annual AAC total.

3. Notable benefits include, as a result of the use of FeNO devices, a 45K reduction in unnecessary prescriptions for inhaled corticosteroid medications.

4. The £33.7M year-to-date cost to the health system was primarily driven by High intensity statins, PCSK9i and Asthma biologics. It should however be noted that the total in-year saving or cost will fluctuate over the course of the year, depending on the volume of uptake of individual innovations and the saving or cost they each deliver per patient.

5. Economic growth metrics, such as investment secured and jobs created, are reported annually by the majority of programmes and so are excluded from the infographic.

Appendix – Programme Deep Dives

Develop a Prioritised Pipeline of Innovation and Research for the NHS:
- **Innovation Service**
- **Horizon Scanning**
- **Demand Signalling**
- **Early Stage Support**

Embed Research in the Everyday Work of the NHS:
- **Research Work Programmes**

Support Stronger Adoption and Spread of Proven Innovations:
- **MedTech Funding Mandate**
- **AI in Health and Care Award**

Develop a Prioritised Pipeline of Innovation and Research for the NHS: Innovation Service

∧CCELERATED ∧CCESS COLLABORATIVE

Programme Aims: Create a national "front door" to the innovation ecosystem, envisaged as an online portal with information, support, and signposting that links to existing teams who provide more detailed advice on aspects of the innovation pipeline.

Key Programme Updates

Information for innovators
- Approval in place for publishing a basic and advanced guide on the website. Innovators are directed to one or the other depending on their answers to questions about their innovation. Three case studies have been completed and will add real examples to the content. Four more are in draft stage, including those with innovators with protected characteristics.

Development
- First version of the working site has been completed and is being tested by innovators and support organisations (AHSNs, Supply chain, NICE etc). The site is in private beta and users can only the access the site using a password. 120 users invited to participate in testing during private beta, with 34 organisational accounts created.
- Feedback being gathered using questionnaires, pop-ups on the site as well as 1:1 interviews with users. Feedback has informed future development pipeline (i.e. site navigation, user journey).
- GDS beta assessment passed on 13th September 2021. This allows us to move into the public beta version of the service.
- A Needs Assessment Team is being set up to provide a first assessment of innovations registering on the system and to select who can support them.

Communications
- An agency (Blush) have been chosen to provide materials (branding, twitter cards, videos, slides) to be used by stakeholders in promoting the service once it is live. A business case is submitted for longer term communications support.
- Large scale comms launch is not planned in the near future. This is to allow the Service to gradually take on more innovations, test and iterate and ensure it is able to cope with working at scale.

Service management
- The intention is to commission out the management of the service, once we have a stable public beta or 'live' service.

Timelines / Upcoming Milestones
- Launch public beta - By end 2021
- Gather feedback from beta to inform functionality and development roadmap – Ongoing
- Close entry to Health Tech Connect and redirect to Innovation Service – timing determined by launch of public beta
- Formal launch date - TBC Winter 2021

A

Key Risks & Mitigations
Risk 1: There is a risk that an incomplete handover of development from the BJSS team to NHSEI IT contractors will result in knowledge loss or a reduction in pace.
Mitigation: A six week handover period has been implemented, joint working, pair programming, knowledge transfer sessions, documentation transfer

Develop a Prioritised Pipeline of Innovation and Research for the NHS: Horizon Scanning

Programme Aims: The central Horizon Scanning team will support the adoption of new technologies into the NHS identifying future innovations for the NHS early so ensuring challenges are identified and planned for.

Key Programme Updates

- In collaboration with stakeholders, the process to operationalise the Horizon Scanning vision for a more strategic proactive scanning process - from early stage glimmers through to late stage uptake.
- Strategic partnerships with industry are being maintained by the initiation of an annual engagement event
- Objective methodology and process has been developed for prioritising inbound requests for targeted/reactive scans.

Live:
- **Upper Limb Prosthetics:** Intelligence to inform clinical policy focused on congenital upper limb deficiency or upper limb amputation and the use of a myoelectric control multi-grip prosthetic for hand, digit or partial hand absence.
- **Advanced Therapy Medicinal Products (ATMPs):** Gather information on the ATMPs landscape up to 2026 to help AAC partners plan for introduction of these into the NHS.
- **AMR:** Review of medical technologies to enhance appropriate antimicrobial prescribing

In draft:
- **Alzheimer's/Dementia:** Analysis across the full clinical pathway to better understand emerging therapeutics and MedTech (non-medicines) that collectively may have a transformational effect on patient outcomes

Timelines / Upcoming Milestones

- Establish task & finish groups for the three pillars of horizon scanning – from early stage glimmers through to late stage uptake – CSU to be commissioned by end Nov 2021
- Implement new process for prioritising inbound requests for targeted scans – Jan 2022
- Design and develop content for next industry engagement event – Mar 2022

G

Key Risks & Mitigations

Risk 1: Resource within team
Mitigation: Planning, structure and prioritisation around deliverables. CSU to be contracted to provide support

Develop a Prioritised Pipeline of Innovation and Research for the NHS: Demand Signalling

Programme Aims: To work with multi-disciplinary stakeholders including clinicians, academics and those with lived experience to articulate the priority research needs and innovation challenges to deliver on ambitions set out in the NHS Long-Term Plan. Research questions will then be signalled out to funders, and innovation challenges will be signalled out to innovators.

Key Programme Updates

- The **Stroke, Learning Disability & Autism, and Mental Health** programmes have completed. Reports for these are either in draft or are passing through the Gateway approvals process for publication.

- Comprehensive **signalling strategy** is being developed alongside funders.

- Lessons learned exercise undertaken and iterative improvements have been made to the process. 'Tranche 2' topics are being considered – in-line with Life Sciences Vision and NHS LTP, current top priorities are **Respiratory, and Primary care**.

- The team have recently recruited to vacant Project Support Officer and Research Officer posts.

Timelines / Upcoming Milestones
- Execute a signalling campaign Stroke, LDA, and MH – Commenced
- Publication of final reports for Stroke, LDA, and MH – Nov 2021
- Initiate 'Tranche 2' Nov 2021

G

Key Risks & Mitigations
Risk 1: Team resource
Mitigation: Planning, structure and prioritisation around deliverables.

Develop a Prioritised Pipeline of Innovation and Research for the NHS: Early Stage Support (ATMPs & HITS)

Programme Aims: The AAC Board agreed in June 2019 to provide support two categories of early stage products; Advanced Therapy Medicinal Products (ATMPs) and Histology Independent Therapies (HITs) to accelerate their adopting into the NHS by addressing key barriers identified for these categories of products.

Key Programme Updates

Significant progress has been achieved by the programme over the last period. Two workstreams have successfully delivered and have been closed down and closure of a further three workstreams has been initiated. We expect the remaining activities for wave 1 to be delivered by March 2022. A paper will be presented at the Steering Group outlining the programme and delivery to date and recommending the conclusion of a AAC partners support for ATMPs and HITs. The Steering Group and Board will be asked to endorse a redesign of phase 2 of the programme to ensure the greatest value offer from AAC partners.

ATMP and HIT Workstream highlights:
- A series of discovery workshops have been facilitated by the Patient & Public Involvement workstream to explore; what patient-facing information is available, understand how people want to access information, and what additional information is needed to improve patient understanding of HITs and ATMPs. The outputs will inform the development of a 'trusted information digital environment'.
- NTRK gene fusion testing for advanced solid tumours is now being offered nationally by all seven NHS Genomic Laboratory Hubs (GLHs). The GLHs are seeing an increase in referrals for genomic testing. Close down for WS11 has been initiated.
- The HIT refresh horizon scan is complete and a process for aligning ongoing scans with existing infrastructure has been agreed. Closed down for WS2 (HITs) has been initiated.
- Development of the ATMP roadmap detailing system roles, responsibilities and support for ATMPs developers is in progress. The framework has been agreed and validation of the content and design is underway.
- Proposed changes to the NICE Methods review are currently out for consultation and include refinements to their methods and processes for selecting and evaluating health technologies to allow committees to apply flexibility around uncertainty posed by complex innovative technologies. The consultation closes on the 13th October 2021.
- Workstream 9 (Regulatory Approval) & Workstream 11 (HITs Pathway Preparedness) have been successfully closed down following delivery.

Next Steps:
- Continue to monitor impact of response to COVID-19 on delivery
- Public engagement on Innovative Medicine Fund (IMF) principles
- An extensive 'lessons learnt' process to evaluate Wave 1
- Develop proposal for phase 2 in collaboration with AAC partners and key stakeholders

Timelines / Upcoming Milestones
- Public animation video launch – Nov 21
- ATMP horizon Scan refresh – Nov 21
- ATMP roadmap launch – Nov/Dec 21
- Publication of NICE Methods review – Dec 21
- Publication of patient experience case studies for ATMPs – Dec 21

G

Key Risks & Mitigations
Issue 1: Lack of information on ILAP/project Orbis topics impacting on service readiness for ATMP product launch / NICE recommendations.
Mitigation: Engage with MHRA and NICE to ensure good communication of upcoming pipeline and timescales. Risk has been escalated to very senior level at NHSE&I.

Risk 1: Bluebird Bio announcement of withdrawal of operations in Europe, potential impact on reputation of the programme and reduce appetite from industry to launch ATMPs in UK.
Mitigation: Continue to monitor the situation and work closely with NHSE/I teams.

Embed Research in the Everyday Work of the NHS: Research Work Programmes

ΛCCELERATED
ΛCCESS
COLLABORATIVE

Programme Aims: Improving patient outcomes by embedding research in healthcare practice across all NHS settings, and increasing the number and diversity of people accessing and taking part in research.

Key Programme Updates

Summary of current research Activity
- Between 1 April to 12 Oct 2021, 460,417 participants have been recruited into Covid research studies in England (an increase of 29,934 in fortnight prior to 12 Oct 21)
- The successful consortium for the new community based antiviral platform study being established will be announced soon.
- Between 1 April to 12 Oct 2021, 232,112 participants (7,617 studies) have been recruited into non-Covid studies (an increase of 29,853 in fortnight prior to 12 Oct 21)

Research Resilience and Growth Programme
- National Clinical Research Vision published on 23 March - https://www.gov.uk/government/publications/the-future-of-uk-clinical-research-delivery. Very high level, setting out five key themes and seven actions including the ambition to embed research in the NHS. Implementation plan published 23 June outlining phased approach to research sector recovery in 2021/22 and future growth The Future of UK Clinical Research Delivery: 2021 to 2022 implementation plan - GOV.UK (www.gov.uk)
- Awaiting outcome of CSR before developing phase 2 of the implementation plan
- NIHR has published an update relating to managing research recovery for non-COVID studies over the next 6 to 12 months.

Cross NHSE/I Research Leadership Group
- NHSE/I Group has been established to bring together teams who have links to research and evaluation and to enable increased cohesion and embedding of research and evaluation practices. This group has met three times, and specific subgroups now planned to mirror the DHSC-led National Clinical Research Vision subgroups. Cross-directorate workforce subgroup has been established.
- An NHSE/I Research Roadmap is under development, which will build upon baseline mapping of organisational research/evaluation activities.

Regional engagement
- NHSE/I have co-ordinated regional research engagement events (North West and London regions, with remaining regional events in preparation) in collaboration with regional Medical Directors and NIHR CRN to support local health and research leaders – including ICS representatives - to prioritise in embedding and capitalising upon regional research.

Excess Treatment Costs
- Excess treatment cost guidance has been uploaded on the NHSE/I website.

Timelines / Upcoming Milestones
- NHSE/I Research Roadmap development – Dec 2021
- Regional engagement event delivery and resultant action plans discussed and agreed by early 2022 – Mar 2022

A/G

Key Risks & Mitigations
Issue 1: Continued impact of COVID-19 on service delivery and how we build research into recovery.
Issue 2: Lack of understanding of the importance of research to NHS & patients
Mitigation 1&2: Built in to the research resilience and growth programme.

Support Stronger Adoption and Spread of Proven Innovations: MedTech Funding Mandate

Programme Aims: The MedTech Funding Mandate aims to accelerate the uptake of selected NICE approved cost-saving medical devices, diagnostics and digital products in the NHS by making their use a contractual requirement for providers and commissioners – meaning patients will get access to these technologies faster.

Key Programme Updates

MedTech Funding Mandate (MTFM) Policy and Guidance:
- Operational management process for the MTFM 21/22 policy in place
- Working with the AHSN to overcome any barriers to adoption due to the replacement of the National Tariff Payment System with funding envelopes
- Working with NICE to understand which MTG and DG guidance meets the 22/23 MTFM criteria
- MTFM team members of the National Pricing Policy Development project group on Aligned Payment Incentives; new policy to future proof funding mechanisms for innovation
- NHS E National Media Team publishing press articles on individual technologies supported by the MTFM with huge success
- Work to understand visibility of use of innovations in mandated national datasets commenced

Next steps: Work with CQC to understand if they will include the compliance of the MTFM in their provider assurance assessments
- Publish a signalling document to the sector in late October listing the eligible technologies to be supported by the MTFM in 2022/23; sent for publishing approval w/c 25/10
- Continue working closely with NHS England National Tariff Pricing Team to understand Aligned Incentive Payment System proposed for 2022/23
- Work with the AHSN National programme lead, to develop the policy delivery in 22/23

Engagement with NHS Supply Chain on MedTech Funding Mandate products
- Continue to work with NHS Supply Chain to finalise reporting to NHS England to understand uptake
- Learn where gaps in data are and what can be done to ensure full capture going forwards

Next steps: Work with NHS Supply Chain to understand the availability of technologies eligible for 22/23 through supply chain

Engagement with suppliers supported by the MTFM 2021/22
- MedTech Funding Mandate Action Learning Set Group continues to meet to discuss programme and overcome challenges faced in transition as a team
- Individual 1:1 monthly meetings held with suppliers to help with transition from ITP to MedTech Funding Mandate

Q1 delivery
- Uptake: GammaCore 89 (first responder cards – year to date); Heartflow 1,433 scans; PLGF 6,025 tests; SecurAcath 8,580 catheters
- Site stage of adoption: Stage 4 - Implementation (Once work is underway in the organisation to implement the innovation/programme) 84 sites; Stage 5: Adoption (Once the innovation/programme is underway within the organisation) 194 sites.

Timelines / Upcoming Milestones
- Understand which technologies meet the 2022/23 MTFM criteria
- Support National Tariff Pricing Team on engagement for an Aligned Incentives Payment Scheme.
- Publish signalling document to the sector in readiness for 2022/23 MTFM – Oct 21
- Publish MTFM 22/23 policy guidance document - Dec 21

AG

Key Risks & Mitigations
Risk 1: Current NHS finance arrangements for H2 means no activity based payment agreements are in place and CCGs are challenging the policy requirements to fund risking compliance.
Mitigation: Working closely with the AHSN leads to identify where supportive conversations are needed. For H2 Strategic Finance publishing some MTFM FAQs to help overcome resilience by commissioners to fund.

Support Stronger Adoption and Spread of Proven Innovations: AI in Health and Care Award

ΛCCELERATED
ΛCCESS
COLLABORATIVE

Programme Aims: To establish the UK as the preeminent destination for developing and scaling health and care AI solutions by:
1. Funding leading AI innovators to develop their technologies in UK
2. Building a world-class real-world AI testing environment in UK
3. Accelerating adoption and spread of proven AI technologies across NHS

Key Programme Updates

Technology Deployment and Contracting
- All (41) Round 1 contracts signed
- 13/15 Round 2 Phase 3+4 contracts signed. 12/23 Round 2 Phase 1+2 contracts signed (R2 contracting process more streamlined than R1)

Evaluation
- 13 applications from Evaluation Partner Group received to evaluate 3 P3 R2 techs and 6 P4 R2 techs. Interviews to be conducted in Oct with appointment by early Nov 21.
- 9/9 Round 1 evaluation scopes now approved by EAG. R1 evaluations underway.
- 7/9 R1 TSET contracts signed with remaining anticipated by end Oct.
- Second draft of commentary on AI study designs reviewed at Sept Evaluation Advisory Group. Aiming to publish in leading academic journal by end of 21/22.

Round 3
- Competition 3 closed 7 Sept, 200 applications received.
- Round 3 winners to be announced in February 2022.

Programme
- PPIE in AI research project commenced, report to be published in Winter 2021/22.
- Operational impact continues to increase, with 170 live project sites and 65.5k patients whose care had been enhanced via Award funding ytd.
- Recruitment of team near completion. New 8A and 8B appointed – to start Nov '21. GMT, Fast Streamer and Comms Manager started in September.
- We have received several positive press articles in national newspapers profiling AI Award winners and the work of AAC.
- AI Award team are exploring opportunities to support NHS elective recovery work (e.g. use cases for PTL risk stratification).
- Project to conduct qualitative research with R1 AI Award winners to understand the drivers and barriers of success and make policy reccs kicked off Oct '21 – reccs due Q4 21/22

Timelines / Upcoming Milestones
- Round 3 Stage 1 Shortlisting - Oct 21
- TSETs appointed for R2 technology evaluations - Nov 21.
- Evaluation Learning Document on AI Study Designs Publication - Q4 21/22
- Results following the completion of the first 7 Phase 1 projects - Q4 21/22
- Round 3 Winners announced – Feb 22
- Round 4 opening for applications - Spring 22

G

Key Risks & Mitigations
UKCA Approval - Risk due to the change from CE Marking to UKCA marking there is a delay in the approval process. This could impact on technologies meeting the entry / exit criteria for the AI Award. **Mitigation plans**: Working closely with applicants to understand if they are experiencing delays.
Adoption: Risk that a national commissioning framework won't be in place once the testing /evaluation phase concludes. **Mitigating plans**: Engagement with national and local commissioning colleagues and national imaging team. Adoption pathway planning work with tech companies. Work with NHSX procurement team.